pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
◐
Sign In
Subscribe
🐶
home
jobs
news
search
Cancer Program · news · pharmadog
← back to Cancer Program
News mentioning Cancer Program
69
stories
12h
Cancer vaccine win restores Wall Street’s faith in Moderna
biopharma dive
16h
Merck’s Moderna-partnered vaccine success clears view of post-Keytruda future
biospace
18h
Merck-Moderna cancer vaccine win spurs stock jump, speculation of Keytruda-like impact
fiercebiotech
1d
Trump's FDA pick Overton good for psychedelics, new pain meds but bad for vaccines: Analysts
biospace
1d
Moderna stock nearly doubles as Merck-partnered mRNA cancer vaccine meets Phase 3 goal
biospace
1d
Moderna and Merck cancer vaccine returns ‘landmark’ result in melanoma
biopharma dive
1d
STAT+: Moderna and Merck say mRNA cancer vaccine succeeded in late-stage melanoma trial
stat
2d
Merck, Moderna’s personalized cancer vaccine slows recurrence in phase 3, setting up approval push
fiercebiotech
2d
Sandoz inks $322M Henlius deal for rights to as many as 10 biosimilars
biospace
2d
Regeneron ends eye disease study due to antibody's safety profile
biospace
2d
Regeneron ends eye disease study due to antibody's safety profile
biospace
3d
AstraZeneca scraps Phase 3 trial of new bispecific in lung cancer
biopharma dive
3d
AstraZeneca pulls plug on late-stage lung cancer trial, taking another clinical blow
biospace
3d
AstraZeneca pulls plug on late-stage lung cancer trial, taking another clinical blow
biospace
4d
AstraZeneca ends phase 3 lung cancer trial after bispecific falls short versus Keytruda
fiercebiotech
7d
PDS halts work on phase 3 cancer therapy to focus on colorectal contender
fiercebiotech
14d
Replimune rebounds to win FDA approval of melanoma drug
biopharma dive
15d
Earnings roundup: Gilead’s ‘uncertain’ future, Pfizer’s crossroads and Merck’s PCSK9 launch
biopharma dive
15d
5 NextGen winners who went public this year (and which ones are hiring)
biospace
16d
Merck plans trial of sac-TMT combo with Keytruda in lung cancer
endpoints
16d
Merck’s $10.8B Prometheus deal delivers another win—plus a Phase 2b miss
biospace
16d
As portfolio erodes, BMS stands to gain a lot from rumored AstraZeneca merger
biospace
17d
Merck’s $11B anti-TL1A bet delivers 1 win, 1 loss in midphase inflammatory disease trials
fiercebiotech
21d
Replimune melanoma drug wins support of FDA panel
biopharma dive
22d
Merck posts—then pulls—trial plan for PD-1xVEGF and TROP2 ADC combination
fiercebiotech
23d
FDA says Replimune’s melanoma data package is ‘not interpretable,’ setting up tough adcomm
biospace
24d
AstraZeneca has no plans to ramp up dealmaking in wake of Wainua failure
biospace
25d
Summit, Merck must navigate new regulatory terrain in China-first cancer landscape
biospace
27d
Summit has less than a year of cash runway left as PD-1/VEGF verdict nears
biospace
28d
Biopharma layoffs must double in H2 for 2026 to match 2025 cuts
biospace
← prev
page 1 of 3
next →
